NFE2L2 and lung carcinoma: Current evidence suggests that mutations in the NRF2/KEAP1 gene may lead to poor prognosis in patients with lung cancer, such as resistance to radiotherapy and chemotherapy, but more specific evidence is needed to validate this 25,26.